Evidence map›Paper›PMID 41157561›Full record

ArticleViruses2025

Screening of Single-Domain Antibodies to Adeno-Associated Viruses with Cross-Serotype Specificity and a Wide pH Tolerance.

Hailing Guo, Shuo Wang, Lujin Feng, Weiwei Xu, Jiandong Zhang, Xiaoju Zhou, Ningning Ma

Abstract read
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hailing GuoWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Shuo WangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.ORCID 0000-0002-6275-9675
Lujin FengWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Weiwei XuYSK Bio Co., Ltd., Zhuji 311899, China.
Jiandong ZhangYSK Bio Co., Ltd., Zhuji 311899, China.
Xiaoju ZhouSchool of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China.
Ningning MaWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.

Funding

National Key Research and Development Program of China 2023YFC3404000
6 · The paper itself

Abstract

Adeno-associated virus (AAV) vectors are the preferred gene delivery tool in gene therapy owing to their safety, long-term gene expression, broad tissue tropism, and low immunogenicity. Affinity ligands that can bind multiple AAV serotypes endure harsh clean-in-place (CIP) conditions and are critical for industrial-scale purification. However, current ligands lack broad serotype recognition and adequate alkaline stability, which limits their reusability in large-scale manufacturing. In this study, we employed a competitive biopanning strategy to isolate a single-domain antibody (VHH) that simultaneously binds AAV2, AAV8, and AAV9. The VHH retained structural integrity and binding activity after exposure to 0.1 M NaOH, demonstrating robust alkaline stability. Structural modeling revealed that the VHH primarily recognizes the DE loop region of the VP3 capsid protein across the three serotypes, explaining its cross-serotype reactivity. Affinity chromatography using the VHH yielded infectious AAV particles, confirming its potential for downstream processing. This strategy provides a versatile platform for developing high-performance AAV affinity ligands and may be extended to other viral vector systems.

Indexed as

Antibodies, ViralDependovirusSingle-Domain AntibodiesCapsid ProteinsCross ReactionsGenetic VectorsHEK293 CellsHumansHydrogen-Ion ConcentrationModels, MolecularSerogroupAntibodies, ViralCapsid ProteinsSingle-Domain AntibodiesAAVaffinity purificationalkaline stabilitycompetitive biopanning strategyVHH

Identifiers

PMID41157561
PMCPMC12568183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.